TPST-4003 / Tempest Therap - LARVOL DELTA

Tempest’s parallel CAR architecture is being applied across multiple programs (GlobeNewswire) - "(i) TPST-3003, an allogeneic CD19/BCMA dual-targeting CAR-T therapy under development for rrMM; (ii) TPST-4003, an in vivo CD19/BCMA dual-targeting CAR-T therapy under development for systemic lupus erythematosus (SLE) and other immunology disorders. Tempest expects initial clinical data from both programs later this year and believes this platform approach may allow these therapies to ultimately benefit a larger number of patients."

Clinical data • Multiple Myeloma • Systemic Lupus Erythematosus